Development of user-friendly cancer risk assessment tools for clinical settings (CanRisk). The main objective of the CanRisk programme is to develop and validate quantitative tools for cancer risk-stratification and prevention that take advantage of discoveries in both cancer genomics and epidemiology
A small number of men and women have inherited faulty genes which means that they are at an increased risk of developing certain cancers. Two of these genes are called BRCA1 and BRCA2. When someone has a fault in these genes they are more likely to develop cancers of the breast, ovary or prostate. The EMBRACE study collects information about people who have inherited faulty breast cancer genes.
Laboratory analysis takes place at Strangeways Laboratory. This includes extraction of DNA, RNA, plasma from blood samples as well as SNP genotyping.
A coordinated multi-centre prospective study investigating biological mechanisms behind normal tissue radiosensitivity.
The SEARCH Study is an ongoing study of genetic susceptibility to the common cancers, the main purpose of which is to determine how normal, common genetic variation affects cancer risk. The study hopes to achieve this by collecting a blood sample and information on family history and lifestyle from men and women in East Anglia who have been diagnosed with specific cancers.
A Genetic Study of Quantitative Phenotypes Related to Breast Cancer. This research is one of many studies going on in Cambridge into breast cancer. It is being run jointly by Addenbrooke’s Hospital and the University of Cambridge, and is funded by Cancer Research UK. We are recruiting women and their female blood relatives from the NHS Breast Screening Programme.
The major goal of this project is to examine the genetic basis of telomere shortening and its effect on risk of breast, colorectal and prostate cancer.